{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:44:33Z","timestamp":1785350673492,"version":"3.55.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11154-018-9478-8","type":"journal-article","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T08:01:06Z","timestamp":1549526466000},"page":"363-395","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Statins, metformin, proprotein-convertase-subtilisin-kexin type-9 (PCSK9) inhibitors and sex hormones: Immunomodulatory properties?"],"prefix":"10.1007","volume":"19","author":[{"given":"Christian A.","family":"Koch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Krabbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Hehmke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,23]]},"reference":[{"issue":"5030","key":"9478_CR1","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1126\/science.1925600","volume":"254","author":"K Karalis","year":"1991","unstructured":"Karalis K, Sano H, Redwine J, Listwak S, Wilder RL, Chrousos GP. Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science. 1991;254(5030):421\u20133.","journal-title":"Science"},{"issue":"20","key":"9478_CR2","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1056\/NEJM199505183322008","volume":"332","author":"GP Chrousos","year":"1995","unstructured":"Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332(20):1351\u201362.","journal-title":"N Engl J Med"},{"key":"9478_CR3","doi-asserted-by":"crossref","unstructured":"Franchimont D, Bouma G, Galon J, Wolkersd\u00f6rfer GW, Haidan A, Chrousos GP, Bornstein SR. Adrenal cortical activation in murine colitis. Gastroenterology 2000 119(6):1560\u20131568.","DOI":"10.1053\/gast.2000.20235"},{"key":"9478_CR4","doi-asserted-by":"crossref","unstructured":"Antonelli A, Ferrari SM, Frascerra S, Di Domenicantonio A, Nicolini A, Ferrari P, Ferrannini E, Fallahi P. Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. J Clin Endocrinol Metab 2011;96(6):1859\u20131863.","DOI":"10.1210\/jc.2010-2905"},{"issue":"9","key":"9478_CR5","first-page":"1809","volume":"35","author":"A Antonelli","year":"2008","unstructured":"Antonelli A, Ferri C, Fallahi P, Colaci M, Giuggioli D, Ferrari SM, et al. Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis. J Rheumatol. 2008;35(9):1809\u201311.","journal-title":"J Rheumatol"},{"key":"9478_CR6","doi-asserted-by":"publisher","unstructured":"Ferrari SM, Fallahi P, Galetta F, Citi E, Benvenga S, Antonelli A. Thyroid disorders induced by checkpoint inhibitors. Rev Endocr Metab Disord. 2018. https:\/\/doi.org\/10.1007\/s11154-018-9463-2 .","DOI":"10.1007\/s11154-018-9463-2"},{"key":"9478_CR7","doi-asserted-by":"crossref","unstructured":"Gubbi S, Hannah-Shmouni F, Stratakis CA, Koch CA. Primary hypophysitis and other autoimmune disorders of the sellar and suprasellar regions. Rev Endocr Metab Disord 2018.","DOI":"10.1007\/s11154-018-9480-1"},{"issue":"6","key":"9478_CR8","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1046\/j.1365-2265.1999.0787b.x","volume":"50","author":"CA Koch","year":"1999","unstructured":"Koch CA, Robyn JA, Pacak K. How do levels of (endogenous) glucocorticoids, interleukin-10 and interleukin-12 relate to multiple sclerosis relapse before, during and after pregnancy? Clin Endocrinol. 1999;50(6):818\u20139.","journal-title":"Clin Endocrinol"},{"issue":"1","key":"9478_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/039463201302600121","volume":"26","author":"E Melcescu","year":"2013","unstructured":"Melcescu E, Kemp EH, Majithia V, Vijayakumar V, Uwaifo GI, Koch CA. Graves' disease, hypoparathyroidism, systemic lupus erythematosus, alopecia, and angioedema: autoimmune polyglandular syndrome variant or coincidence? Int J Immunopathol Pharmacol. 2013;26(1):217\u201322.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"3","key":"9478_CR10","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.yexmp.2012.09.025","volume":"93","author":"E Melcescu","year":"2012","unstructured":"Melcescu E, Hogan RB 2nd, Brown K, Boyd SA, Abell TL, Koch CA. The various faces of autoimmune endocrinopathies: non-tumoral hypergastrinemia in a patient with lymphocytic colitis and chronic autoimmune gastritis. Exp Mol Pathol. 2012;93(3):434\u201340.","journal-title":"Exp Mol Pathol"},{"issue":"1","key":"9478_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11154-016-9339-2","volume":"17","author":"M Nati","year":"2016","unstructured":"Nati M, Haddad D, Birkenfeld AL, Koch CA, Chavakis T, Chatzigeorgiou A. The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH). Rev Endocr Metab Disord. 2016;17(1):29\u201339.","journal-title":"Rev Endocr Metab Disord"},{"issue":"12","key":"9478_CR12","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.2337\/diab.44.12.1414","volume":"44","author":"B Hehmke","year":"1995","unstructured":"Hehmke B, Michaelis D, Gens E, Laube F, Kohnert KD. Aberrant activation of CD8+ T-cell and CD8+ T-cell subsets in patients with newly diagnosed IDDM. Diabetes. 1995;44(12):1414\u20139.","journal-title":"Diabetes"},{"issue":"4","key":"9478_CR13","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1046\/j.1526-0968.2000.004004296.x","volume":"4","author":"B Hehmke","year":"2000","unstructured":"Hehmke B, Salzsieder E, Matic GB, Winkler RE, Tiess M, Ramlow W. Immunoadsorption of immunoglobulins alters intracytoplasmic type 1 and type 2 T cell cytokine production in patients with refractory autoimmune diseases. Ther Apher. 2000;4(4):296\u2013302.","journal-title":"Ther Apher"},{"issue":"7640","key":"9478_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature21363","volume":"542","author":"GS Hotamisligil","year":"2017","unstructured":"Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542(7640):177\u201385.","journal-title":"Nature"},{"issue":"6123","key":"9478_CR15","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.1233521","volume":"339","author":"JG Markle","year":"2013","unstructured":"Markle JG, Frank DN, Mortin-Toth S, Robertson CE, Feazel LM, Rolle-Kampczyk U, et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science. 2013;339(6123):1084\u20138.","journal-title":"Science"},{"issue":"2","key":"9478_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2174\/157015912800604542","volume":"10","author":"M Martino","year":"2012","unstructured":"Martino M, Rocchi G, Escelsior A, Fornaro M. Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin\/Norepinephrine Balance and Th1\/Th2 Balance. Curr Neuropharmacol. 2012;10(2):97\u2013123.","journal-title":"Curr Neuropharmacol"},{"issue":"4","key":"9478_CR17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1159\/000334612","volume":"95","author":"P Ameri","year":"2012","unstructured":"Ameri P, Ferone D. Diffuse endocrine system, neuroendocrine tumors and immunity: what\u2019s new ? Neuroendocrinology. 2012;95(4):267\u201376.","journal-title":"Neuroendocrinology"},{"key":"9478_CR18","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.4049\/jimmunol.149.11.3621","volume":"149","author":"AM Blum","year":"1992","unstructured":"Blum AM, Metwali A, Mathew RC, Cook G, Elliott D, Weinstock JV. Granuloma T lymphocytes in murine schistosomiasis mansoni have somatostatin receptors and respond to somatostatin with decreased IFN-gamma secretion. J Immunol. 1992;149:3621.","journal-title":"J Immunol"},{"issue":"2","key":"9478_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11154-018-9470-3","volume":"19","author":"E Bhanat","year":"2018","unstructured":"Bhanat E, Koch CA, Parmar R, Garla V, Vijayakumar V. Somatostatin receptor expression in non-classical locations - clinical relevance? Rev Endocr Metab Disord. 2018;19(2):123\u201332.","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"9478_CR20","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1055\/s-0030-1270522","volume":"43","author":"T Lincke","year":"2011","unstructured":"Lincke T, Orschekowski G, Singer J, Sabri O, Paschke R. Increased gallium-68 DOTATOC uptake in normal thyroid gland. Horm Metab Res. 2011;43(4):282\u20136.","journal-title":"Horm Metab Res"},{"issue":"2","key":"9478_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s11154-018-9473-0","volume":"19","author":"CA Koch","year":"2018","unstructured":"Koch CA, Petersenn S. Black swans - neuroendocrine tumors of rare locations. Rev Endocr Metab Disord. 2018;19(2):111\u201321.","journal-title":"Rev Endocr Metab Disord"},{"issue":"14","key":"9478_CR22","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1016\/j.jacc.2017.01.060","volume":"69","author":"JM Tarkin","year":"2017","unstructured":"Tarkin JM, Joshi FR, Evans NR, Chowdhury MM, Figg NL, Shah AV, et al. Detection of atherosclerotic inflammation by 68Ga-DOTATATE PET compared to 18F FDG PET imaging. J Am Coll Cardiol. 2017;69(14):1774\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"9478_CR23","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00210-016-1252-4","volume":"389","author":"O Bedi","year":"2016","unstructured":"Bedi O, Dhawan V, Sharma PL, Kumar P. Pleiotropic effects of statins: new therapeutic targets in drug design. Naunyn Schmiedeberg's Arch Pharmacol. 2016;389(7):695\u2013712.","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"issue":"2","key":"9478_CR24","first-page":"93","volume":"67","author":"DP Troeman","year":"2013","unstructured":"Troeman DP, Postma DF, van Werkhoven CH, Oosterheert JJ. The immunomodulatory effects of statins in community-acquired pneumonia: a systematic review. J Inf Secur. 2013;67(2):93\u2013101.","journal-title":"J Inf Secur"},{"issue":"1","key":"9478_CR25","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12974-017-0934-2","volume":"14","author":"X Xu","year":"2017","unstructured":"Xu X, Gao W, Cheng S, Yin D, Li F, Wu Y, et al. Anti-inflammatory and immunomodulatory mechanisms of atorvastatin in a murine model of traumatic brain injury. J Neuroinflammation. 2017;14(1):167.","journal-title":"J Neuroinflammation"},{"issue":"2","key":"9478_CR26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s11938-018-0180-4","volume":"16","author":"C Moctezuma-Vel\u00e1zquez","year":"2018","unstructured":"Moctezuma-Vel\u00e1zquez C, Abraldes JG, Montano-Loza AJ. The use of statins in patients with chronic liver disease and cirrhosis. Curr Treat Options Gastroenterol. 2018;16(2):226\u201340.","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"4","key":"9478_CR27","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/cen.12600","volume":"82","author":"L Mascitelli","year":"2015","unstructured":"Mascitelli L, Goldstein MR. Statin immunomodulation and thyroid cancer. Clin Endocrinol. 2015;82(4):620.","journal-title":"Clin Endocrinol"},{"issue":"5","key":"9478_CR28","doi-asserted-by":"publisher","first-page":"706","DOI":"10.2174\/1871520613666131129105035","volume":"14","author":"NG Vallianou","year":"2014","unstructured":"Vallianou NG, Kostantinou A, Kougias M, Kazazis C. Statins and cancer. Anti Cancer Agents Med Chem. 2014;14(5):706\u201312.","journal-title":"Anti Cancer Agents Med Chem"},{"key":"9478_CR29","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.atherosclerosis.2005.08.013","volume":"186","author":"WR Coward","year":"2006","unstructured":"Coward WR, Chow SC. Effect of atorvastatin on TH1 and TH2 cytokine secreting cells during T cell activation and differentiation. Atherosclerosis. 2006;186:302\u20139.","journal-title":"Atherosclerosis"},{"key":"9478_CR30","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(98)05917-0","volume":"353","author":"RS Rosenson","year":"1999","unstructured":"Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet. 1999;353:983\u20134.","journal-title":"Lancet"},{"issue":"12","key":"9478_CR31","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1111\/j.1440-1681.2006.04493.x","volume":"33","author":"M Bruegel","year":"2006","unstructured":"Bruegel M, Teupser D, Haffner I, Mueller M, Thiery J. Statins reduce macrophage inflammatory protein-1alpha expression in human activated monocytes. Clin Exp Pharmacol Physiol. 2006;33(12):1144\u20139.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"9478_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.phrs.2014.03.001","volume":"88","author":"C Ulivieri","year":"2014","unstructured":"Ulivieri C, Baldari CT. Statins: from cholesterol-lowering drugs to novel immunomodulators for the treatment of Th17-mediated autoimmune diseases. Pharmacol Res. 2014;88:41\u201352.","journal-title":"Pharmacol Res"},{"key":"9478_CR33","doi-asserted-by":"publisher","first-page":"434586","DOI":"10.1155\/2013\/434586","volume":"2013","author":"A Jameel","year":"2013","unstructured":"Jameel A, Ooi KG, Jeffs NR, Galatowicz G, Lightman SL, Calder VL. Statin Modulation of Human T-Cell Proliferation, IL-1\u03b2 and IL-17 Production, and IFN-\u03b3 T Cell Expression: Synergy with Conventional Immunosuppressive Agents. Int J Inflam. 2013;2013:434586.","journal-title":"Int J Inflam"},{"issue":"2\u20133","key":"9478_CR34","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s12026-013-8409-8","volume":"56","author":"S Khattri","year":"2013","unstructured":"Khattri S, Zandman-Goddard G. Statins and autoimmunity. Immunol Res. 2013 Jul;56(2\u20133):348\u201357.","journal-title":"Immunol Res"},{"key":"9478_CR35","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.2337\/diabetes.55.04.06.db05-1261","volume":"55","author":"B Lozanoska-Ochser","year":"2006","unstructured":"Lozanoska-Ochser B, Barone F, Pitzalis C, et al. Atorvastatin fails to prevent the development of autoimmune diabetes despite inhibition of pathogenic beta-cell-specific CD8 T-cells. Diabetes. 2006;55:1004\u201310.","journal-title":"Diabetes"},{"issue":"2","key":"9478_CR36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2174\/1871530317666171116115120","volume":"18","author":"PJ Kotyla","year":"2018","unstructured":"Kotyla PJ, Kucharz EJ. Statins Therapy for Connective Tissue Diseases: New Therapeutic Opportunities. Endocr Metab Immune Disord Drug Targets. 2018;18(2):135\u201347.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"4","key":"9478_CR37","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/imm.12662","volume":"149","author":"A Lei","year":"2016","unstructured":"Lei A, Yang Q, Li X, Chen H, Shi M, Xiao Q, et al. Atorvastatin promotes the expansion of myeloid-derived suppressor cells and attenuates murine colitis. Immunology. 2016;149(4):432\u201346.","journal-title":"Immunology"},{"issue":"3","key":"9478_CR38","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1097\/MIB.0000000000000640","volume":"22","author":"J C\u00f4t\u00e9-Daigneault","year":"2016","unstructured":"C\u00f4t\u00e9-Daigneault J, Mehandru S, Ungaro R, Atreja A, Colombel JF. Potential Immunomodulatory Effects of Statins in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22(3):724\u201332.","journal-title":"Inflamm Bowel Dis"},{"key":"9478_CR39","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ejphar.2005.05.005","volume":"516","author":"MM Barsante","year":"2005","unstructured":"Barsante MM, Roffe E, Yokoro CM, et al. Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. Eur J Pharmacol. 2005;516:282\u20139.","journal-title":"Eur J Pharmacol"},{"key":"9478_CR40","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.4049\/jimmunol.170.3.1524","volume":"170","author":"BP Leung","year":"2003","unstructured":"Leung BP, Sattar N, Crilly A, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol. 2003;170:1524\u201330.","journal-title":"J Immunol"},{"issue":"7","key":"9478_CR41","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1093\/rheumatology\/keh194","volume":"43","author":"R Cate ten","year":"2004","unstructured":"ten Cate R, Nibbering PH, Bredius RG. Therapy-refractory systemic juvenile idiopathic arthritis successfully treated with statins. Rheumatology (Oxford). 2004;43(7):934\u20135.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"9478_CR42","first-page":"69","volume":"33","author":"S Lv","year":"2015","unstructured":"Lv S, Liu Y, Zou Z, Li F, Zhao S, Shi R, et al. The impact of statins therapy on disease activity and inflammatory factor in patients with rheumatoid arthritis: a meta-analysis. Clin Exp Rheumatol. 2015;33(1):69\u201376.","journal-title":"Clin Exp Rheumatol"},{"issue":"9426","key":"9478_CR43","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(04)16449-0","volume":"363","author":"DW McCarey","year":"2004","unstructured":"McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet. 2004;363(9426):2015\u201321.","journal-title":"Lancet"},{"issue":"2","key":"9478_CR44","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.cellimm.2011.08.015","volume":"271","author":"XL Li","year":"2011","unstructured":"Li XL, Dou YC, Liu Y, Shi CW, Cao LL, Zhang XQ, et al. Atorvastatin ameliorates experimental autoimmune neuritis by decreased Th1\/Th17 cytokines and up-regulated T regulatory cells. Cell Immunol. 2011;271(2):455\u201361.","journal-title":"Cell Immunol"},{"key":"9478_CR45","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1084\/jem.20021425","volume":"197","author":"O Aktas","year":"2003","unstructured":"Aktas O, Waiczies S, Smorodchenko A, et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting TH1 cells through atorvastatin. J Exp Med. 2003;197:725\u201333.","journal-title":"J Exp Med"},{"key":"9478_CR46","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1212\/WNL.59.7.990","volume":"59","author":"O Neuhaus","year":"2002","unstructured":"Neuhaus O, Strasser-Fuchs S, Fazekas F, et al. Statins as immunomodulators: comparison with interferon-beta 1-beta in MS. Neurology. 2002;59:990\u20137.","journal-title":"Neurology"},{"key":"9478_CR47","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/S0140-6736(04)16205-3","volume":"363","author":"T Vollmer","year":"2004","unstructured":"Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. 2004;363:1607\u20138.","journal-title":"Lancet"},{"issue":"2","key":"9478_CR48","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.intimp.2014.10.004","volume":"23","author":"XL Li","year":"2014","unstructured":"Li XL, Zhang ZC, Zhang B, Jiang H, Yu CM, Zhang WJ, et al. Atorvastatin calcium in combination with methylprednisolone for the treatment of multiple sclerosis relapse. Int Immunopharmacol. 2014;23(2):546\u20139.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"9478_CR49","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.4049\/jimmunol.126.6.2093","volume":"126","author":"JA Cuthbert","year":"1981","unstructured":"Cuthbert JA, Lipsky PE. Sterol metabolism and lymphocyte responsiveness: inhibition of endogenous sterol synthesis prevents mitogen-induced human T cell proliferation. J Immunol. 1981;126(6):2093\u20139.","journal-title":"J Immunol"},{"issue":"1","key":"9478_CR50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0162-3109(96)00108-7","volume":"34","author":"S Kurakata","year":"1996","unstructured":"Kurakata S, Kada M, Shimada Y, Komai T, Nomoto K. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology. 1996;34(1):51\u201361.","journal-title":"Immunopharmacology"},{"issue":"12","key":"9478_CR51","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/82219","volume":"6","author":"B Kwak","year":"2000","unstructured":"Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6(12):1399\u2013402.","journal-title":"Nat Med"},{"issue":"1","key":"9478_CR52","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1001\/jama.286.1.64","volume":"286","author":"MA Albert","year":"2001","unstructured":"Albert MA, Danielson E, Rifai N, Ridker PM, Investigators PRINCE. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation\/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286(1):64\u201370.","journal-title":"JAMA"},{"issue":"1","key":"9478_CR53","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0021-9150(02)00316-7","volume":"166","author":"MA Ree van de","year":"2003","unstructured":"van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C, DALI-Study Group. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis. 2003;166(1):129\u201335.","journal-title":"Atherosclerosis"},{"issue":"2","key":"9478_CR54","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1136\/ard.2006.051672","volume":"66","author":"VP Halm van","year":"2007","unstructured":"van Halm VP, Nielen MM, Nurmohamed MT, van Schaardenburg D, Reesink HW, Voskuyl AE, et al. van der Horst-Bruinsma IE, Dijkmans BA.Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis. 2007;66(2):184\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"9478_CR55","doi-asserted-by":"publisher","first-page":"e9418","DOI":"10.1371\/journal.pone.0009418","volume":"5","author":"L Gruaz","year":"2010","unstructured":"Gruaz L, Delucinge-Vivier C, Descombes P, Dayer JM, Burger D. Blockade of T cell contact-activation of human monocytes by high-density lipoproteins reveals a new pattern of cytokine and inflammatory genes. PLoS One. 2010;5(2):e9418.","journal-title":"PLoS One"},{"issue":"4","key":"9478_CR56","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","volume":"6","author":"G Kahaly","year":"2018","unstructured":"Kahaly G, et al. Mycophenolate plus methylprednisolone vs. methylprednisolone alone in active, moderate to severe graves orbitopathy (MINGO): a randomized, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 2018;6(4):287\u201398.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"9478_CR57","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","volume":"5","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, et al. The 2016 European thyroid association\/European group on graves Orbitopathy guidelines for the Management of Graves Orbitopathy. Eur Thyroid J. 2016;5(1):9\u201326.","journal-title":"Eur Thyroid J"},{"issue":"1","key":"9478_CR58","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/SMJ.0000000000000038","volume":"107","author":"E Melcescu","year":"2014","unstructured":"Melcescu E, Horton WB, Kim D, Vijayakumar V, Corbett JJ, Crowder KW, et al. Graves orbitopathy: update on diagnosis and therapy. South Med J. 2014;107(1):34\u201343.","journal-title":"South Med J"},{"key":"9478_CR59","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s12020-015-0762-z","volume":"53","author":"M Bifulco","year":"2016","unstructured":"Bifulco M, Ciaglia E. Statin reduces orbitopathy risk in patients with graves\u2019 disease by modulating apoptosis and autophagy activities. Endocrine. 2016;53:649\u201350.","journal-title":"Endocrine"},{"key":"9478_CR60","doi-asserted-by":"crossref","unstructured":"Liao KL, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005:89\u2013118.","DOI":"10.1146\/annurev.pharmtox.45.120403.095748"},{"key":"9478_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2217\/14796708.3.2.153","volume":"3","author":"S Markovic-Plese","year":"2008","unstructured":"Markovic-Plese S, Singh AK, Singh I. Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair. Future Neurol. 2008;3:1\u201321.","journal-title":"Future Neurol"},{"key":"9478_CR62","first-page":"905","volume":"80","author":"M Soliman","year":"1995","unstructured":"Soliman M, et al. T-cells recognise multiple epitopes in the human thyrotropin receptor extracellular domain. J Clin Endocrinol Metab. 1995;80:905\u201314.","journal-title":"J Clin Endocrinol Metab"},{"key":"9478_CR63","first-page":"1597","volume":"80","author":"EL Fisfalen","year":"1995","unstructured":"Fisfalen EL, et al. Proliferative responses of T-cells to thyroid antigens and synthetic thyroid peroxidase peptides in autoimmune thyroid disease. J Clin Endocrinol Metab. 1995;80:1597\u2013604.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9478_CR64","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1365-2125.2011.03907.x","volume":"72","author":"L Bj\u00f6rkhem-Bergman","year":"2011","unstructured":"Bj\u00f6rkhem-Bergman L, Lindh JD, Bergman P. What is a relevant statin concentration in cell experiments claiming pleiotropic effects? Br J Clin Pharmacol. 2011;72(1):164\u20135.","journal-title":"Br J Clin Pharmacol"},{"key":"9478_CR65","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/nrd1901","volume":"4","author":"MK Jain","year":"2005","unstructured":"Jain MK, Ridker PM. Antiinflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005;4:977\u201387.","journal-title":"Nat Rev Drug Discov"},{"key":"9478_CR66","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nature01158","volume":"420","author":"S Yousseff","year":"2002","unstructured":"Yousseff S, Stuve O, Patarryo JC, Ruiz P, Radosevich JL, Hur EM, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420:78\u201384.","journal-title":"Nature"},{"key":"9478_CR67","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jsbmb.2016.12.004","volume":"167","author":"N Gleicher","year":"2017","unstructured":"Gleicher N, Kushnir VA, Darmon SK, Wang Q, Zhang L, Albertini DF, et al. New PCOS-like phenotype in older infertile women of likely autoimmune adrenal etiology with high AMH but low androgens. J Steroid Biochem Mol Biol. 2017;167:144\u201352.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"2","key":"9478_CR68","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1210\/jc.2006-1988","volume":"92","author":"B Banaszewska","year":"2007","unstructured":"Banaszewska B, Pawelczyk L, Spaczynski RZ, Dziura J, Duleba AJ. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J Clin Endocrinol Metab. 2007;92(2):456\u201361.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9478_CR69","doi-asserted-by":"publisher","first-page":"e007280","DOI":"10.1136\/bmjopen-2014-007280","volume":"5","author":"J Sun","year":"2015","unstructured":"Sun J, Yuan Y, Cai R, Sun H, Zhou Y, Wang P, et al. An investigation into the therapeutic effects of statins with metformin on polycystic ovary syndrome: a meta-analysis of randomised controlled trials. BMJ Open. 2015;5(3):e007280.","journal-title":"BMJ Open"},{"issue":"6","key":"9478_CR70","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1073\/pnas.1417636112","volume":"112","author":"S Eikawa","year":"2015","unstructured":"Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A. 2015;112(6):1809\u201314.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9478_CR71","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.arr.2018.10.003","volume":"48","author":"F Prattichizzo","year":"2018","unstructured":"Prattichizzo F, Giuliani A, Mens\u00e0 E, Sabbatinelli J, De Nigris V, Rippo MR, et al. Pleiotropic effects of metformin: Shaping the microbiome to manage type 2 diabetes and postpone ageing. Ageing Res Rev. 2018;48:87\u201398.","journal-title":"Ageing Res Rev"},{"issue":"26","key":"9478_CR72","doi-asserted-by":"publisher","first-page":"40767","DOI":"10.18632\/oncotarget.8194","volume":"7","author":"YK Chae","year":"2016","unstructured":"Chae YK, Arya A, Malecek MK, Shin DS, Carneiro B, Chandra S, et al. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget. 2016;7(26):40767\u201380.","journal-title":"Oncotarget"},{"issue":"5","key":"9478_CR73","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1001\/jamaneurol.2015.4807","volume":"73","author":"L Negrotto","year":"2016","unstructured":"Negrotto L, Farez MF, Correale J. Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis. JAMA Neurol. 2016;73(5):520\u20138.","journal-title":"JAMA Neurol"},{"key":"9478_CR74","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jneuroim.2016.01.014","volume":"292","author":"Y Sun","year":"2016","unstructured":"Sun Y, Tian T, Gao J, Liu X, Hou H, Cao R, et al. Metformin ameliorates the development of experimental autoimmune encephalomyelitis by regulating T helper 17 and regulatory T cells in mice. J Neuroimmunol. 2016;292:58\u201367.","journal-title":"J Neuroimmunol"},{"key":"9478_CR75","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.intimp.2013.03.020","volume":"16","author":"KY Kang","year":"2013","unstructured":"Kang KY, Kim YK, Kim J, Jung HR, Kim IJ, Cho JH, et al. Ju JH. Metformin downregulates Th17 differentiation and attenuates murine autoimmune arthritis. Int Immunopharmacol. 2013;16:85\u201392.","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"9478_CR76","doi-asserted-by":"publisher","first-page":"e0135858","DOI":"10.1371\/journal.pone.0135858","volume":"10","author":"SY Lee","year":"2015","unstructured":"Lee SY, Lee SH, Yang EJ, Kim EK, Kim JK, Shin DY, et al. Metformin ameliorates inflammatory bowel disease by suppression of the STAT3 signaling pathway and regulation of the between Th17\/Treg balance. Plos One. 2015;10(9):e0135858.","journal-title":"Plos One"},{"issue":"7581","key":"9478_CR77","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nature15766","volume":"528","author":"K Forslund","year":"2015","unstructured":"Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015 Dec 10;528(7581):262\u20136.","journal-title":"Nature"},{"key":"9478_CR78","doi-asserted-by":"publisher","first-page":"10410","DOI":"10.1038\/ncomms10410","volume":"7","author":"K Korpela","year":"2016","unstructured":"Korpela K, Salonen A, Virta LJ, Kekkonen RA, Forslund K, Bork P, et al. Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-school children. Nat Commun. 2016;7:10410.","journal-title":"Nat Commun"},{"issue":"6","key":"9478_CR79","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.numecd.2017.02.007","volume":"27","author":"\u00c9 Csongr\u00e1di","year":"2017","unstructured":"Csongr\u00e1di \u00c9, K\u00e1pl\u00e1r M, Nagy B Jr, Koch CA, Juh\u00e1sz A, Bajnok L, et al. Adipokines as atherothrombotic risk factors in obese subjects: Associations with haemostatic markers and common carotid wall thickness. Nutr Metab Cardiovasc Dis. 2017;27(6):571\u201380.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"3","key":"9478_CR80","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1055\/s-0030-1270521","volume":"43","author":"MI Ullah","year":"2011","unstructured":"Ullah MI, Washington T, Kazi M, Tamanna S, Koch CA. Testosterone deficiency as a risk factor for cardiovascular disease. Horm Metab Res. 2011;43(3):153\u201364.","journal-title":"Horm Metab Res"},{"issue":"3","key":"9478_CR81","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11154-016-9393-9","volume":"17","author":"K Karimi","year":"2016","unstructured":"Karimi K, Lindgren TH, Koch CA, Brodell RT. Obesity as a risk factor for malignant melanoma and non-melanoma skin cancer. Rev Endocr Metab Disord. 2016;17(3):389\u2013403.","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"9478_CR82","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11154-016-9358-z","volume":"17","author":"JB Turner","year":"2016","unstructured":"Turner JB, Kumar A, Koch CA. The effects of indoor and outdoor temperature on metabolic rate and adipose tissue - the Mississippi perspective on the obesity epidemic. Rev Endocr Metab Disord. 2016;17(1):61\u201371.","journal-title":"Rev Endocr Metab Disord"},{"issue":"2","key":"9478_CR83","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11154-016-9383-y","volume":"17","author":"CA Koch","year":"2016","unstructured":"Koch CA. EDITORIAL: \"The Koch's\" view on the sense of taste in endocrinology. Rev Endocr Metab Disord. 2016;17(2):143\u20137.","journal-title":"Rev Endocr Metab Disord"},{"key":"9478_CR84","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ijcard.2018.05.072","volume":"270","author":"K Isoda","year":"2018","unstructured":"Isoda K, Akita K, Kitamura K, Sato-Okabayashi Y, Kadoguchi T, Isobe S, et al. Inhibition of interleukin-1 suppresses angiotensin II-induced aortic inflammation and aneurysm formation. Int J Cardiol. 2018;270:221\u20137.","journal-title":"Int J Cardiol"},{"issue":"35","key":"9478_CR85","doi-asserted-by":"publisher","first-page":"14948","DOI":"10.1073\/pnas.0903958106","volume":"106","author":"M Platten","year":"2009","unstructured":"Platten M, Youssef S, Hur EM, Ho PP, Han MH, Lanz TV, et al. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc Natl Acad Sci U S A. 2009;106(35):14948\u201353.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"9478_CR86","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/art.21040","volume":"52","author":"K Sagawa","year":"2005","unstructured":"Sagawa K, Nagatani K, Komagata Y, Yamamoto K. Angiotensin receptor blockers suppress antigen-specific T cell responses and ameliorate collagen-induced arthritis in mice. Arthritis Rheum. 2005;52(6):1920\u20138.","journal-title":"Arthritis Rheum"},{"issue":"8390","key":"9478_CR87","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/S0140-6736(84)91821-X","volume":"1","author":"MF Martin","year":"1984","unstructured":"Martin MF, Surrall KE, McKenna F, Dixon JS, Bird HA, Wright V. Captopril: a new treatment for rheumatoid arthritis? Lancet. 1984;1(8390):1325\u20138.","journal-title":"Lancet"},{"issue":"5","key":"9478_CR88","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/sji.12218","volume":"80","author":"P Andersson","year":"2014","unstructured":"Andersson P, Bratt J, Heimb\u00fcrger M, Cederholm T, Palmblad J. Inhibition of neutrophil-dependent cytotoxicity for human endothelial cells by ACE inhibitors. Scand J Immunol. 2014;80(5):339\u201345.","journal-title":"Scand J Immunol"},{"issue":"2","key":"9478_CR89","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jid.2017.09.030","volume":"138","author":"P Abadir","year":"2018","unstructured":"Abadir P, Hosseini S, Faghih M, Ansari A, Lay F, Smith B, et al. Topical reformulation of valsartan for treatment of chronic diabetic wounds. J Invest Dermatol. 2018;138(2):434\u201343.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"9478_CR90","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","volume":"72","author":"RS Rosenson","year":"2018","unstructured":"Rosenson RS, Hegele RA, Fazio S, Cannon CP. The evolving future of PCSK9 inhibitors. J Am Coll Cardiol. 2018;72(3):314\u201329.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 2","key":"9478_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP171764.APPGL","volume":"23","author":"PS Jellinger","year":"2017","unstructured":"Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American association of clinical endocrinologists and American College of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(Suppl 2):1\u201387.","journal-title":"Endocr Pract"},{"issue":"5","key":"9478_CR92","doi-asserted-by":"publisher","first-page":"462","DOI":"10.5551\/jat.RV17003","volume":"24","author":"MD Shapiro","year":"2017","unstructured":"Shapiro MD, Fazio S. PCSK9 and atherosclerosis - lipids and beyond. J Atheroscler Thromb. 2017;24(5):462\u201372.","journal-title":"J Atheroscler Thromb"},{"issue":"258","key":"9478_CR93","doi-asserted-by":"publisher","first-page":"258ra143","DOI":"10.1126\/scitranslmed.3008782","volume":"6","author":"KR Walley","year":"2014","unstructured":"Walley KR, Thain KR, Russell JA, Reilly MP, Meyer NJ, Ferguson JF, et al. Boyd JH. PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci Transl Med. 2014;6(258):258ra143.","journal-title":"Sci Transl Med"},{"key":"9478_CR94","doi-asserted-by":"publisher","unstructured":"Liu A, Frosteg\u00e5rd J. PCSK9 plays a novel immunological role in oxidized LDL-induced dendritic cell maturation and activation of T cells from human blood and atherosclerotic plaque. J Intern Med. 2018. https:\/\/doi.org\/10.1111\/joim.12758 .","DOI":"10.1111\/joim.12758"},{"key":"9478_CR95","doi-asserted-by":"crossref","unstructured":"Theocharidou E, Papademetriou M, Reklou A, Sachinidis A, Boutari C, Giouleme O. The role of PCSK9 in the pathogenesis of non-alcoholic fatty liver disease and the effect of PCSK9 inhibitors. Curr Pharm Des 2018.","DOI":"10.2174\/1381612824666181010123127"},{"issue":"1","key":"9478_CR96","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1210\/jc.2012-2382","volume":"98","author":"KA Groth","year":"2013","unstructured":"Groth KA, Skakkeb\u00e6k A, H\u00f8st C, Gravholt CH, Bojesen A. Clinical review: Klinefelter syndrome--a clinical update. J Clin Endocrinol Metab. 2013;98(1):20\u201330.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"9478_CR97","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrendo.2009.212","volume":"5","author":"M Zitzmann","year":"2009","unstructured":"Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol. 2009;5(12):673\u201381.","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"9478_CR98","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1530\/EJE-11-0221","volume":"165","author":"F Saad","year":"2011","unstructured":"Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165(5):675\u201385.","journal-title":"Eur J Endocrinol"},{"issue":"Pt 1","key":"9478_CR99","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/brain\/aws284","volume":"136","author":"R Hussain","year":"2013","unstructured":"Hussain R, Ghoumari AM, Bielecki B, Steibel J, Boehm N, Liere P, et al. The neural androgen receptor: a therapeutic target for myelin repair in chronic demyelination. Brain. 2013;136(Pt 1):132\u201346.","journal-title":"Brain"},{"issue":"6","key":"9478_CR100","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1212\/WNL.0b013e31828154f3","volume":"80","author":"A Langer-Gould","year":"2013","unstructured":"Langer-Gould A, Brara SM, Beaber BE, Koebnick C. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology. 2013;80(6):548\u201352.","journal-title":"Neurology"},{"key":"9478_CR101","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1749-6632.2000.tb05374.x","volume":"917","author":"IJ Elenkov","year":"2000","unstructured":"Elenkov IJ, Chrousos GP, Wilder RL. Neuroendocrine regulation of IL-12 and TNF-alpha\/IL-10 balance. Clinical implications. Ann N Y Acad Sci. 2000;917:94\u2013105.","journal-title":"Ann N Y Acad Sci"},{"key":"9478_CR102","doi-asserted-by":"crossref","unstructured":"Crisp\u00edn JC, Tsokos GC. IL-17 in Systemic Lupus Erythematosus. J Biomed Biotechnol. 2010:1\u20134.","DOI":"10.1155\/2010\/943254"},{"issue":"2","key":"9478_CR103","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1365-2249.2009.03944.x","volume":"157","author":"A Nalbandian","year":"2009","unstructured":"Nalbandian A, Crisp\u00edn JC, Tsokos GC. Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol. 2009;157(2):209\u2013215.","journal-title":"Clin Exp Immunol."},{"key":"9478_CR104","unstructured":"Dey ID, Isenberg DA, Lahita RG. How hormones affect lupus treatment. Endocrine news, 2012."},{"issue":"2","key":"9478_CR105","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.yhbeh.2012.10.014","volume":"63","author":"FP Gomez","year":"2013","unstructured":"Gomez FP, Steelman AJ, Young CR, Welsh CJ. Hormone and immune system interactions in demyelinating disease. Horm Behav. 2013;63(2):315\u201321.","journal-title":"Horm Behav"}],"updated-by":[{"DOI":"10.1007\/s11154-019-09493-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,3,23]],"date-time":"2019-03-23T00:00:00Z","timestamp":1553299200000}}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11154-018-9478-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-018-9478-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-018-9478-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T12:48:57Z","timestamp":1694609337000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11154-018-9478-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":105,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["9478"],"URL":"https:\/\/doi.org\/10.1007\/s11154-018-9478-8","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"23 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2019","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors would like to note that several errors had occurred, especially in Table 2, Tables 5, 6 and 7, Figure 13, and in the legend of Figure 23.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients have provided informed consent for the off label use of statins and for permission to conduct experiments and publish the results. One case study with Graves\u2019s orbitopathy has been published in poster format at the Endocrine Society Meeting 2018 in Chicago: Statins As Immunomodulatory Therapy In Graves\u2019 Orbitopathy. Poster Presentation SAT-676, 100th Endocrine Society Meeting, Chicago, IL, March 17, 2018.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Prof. Koch declares no direct conflict with this article. He has served on the Advisory Board of Novartis on the topic acromegaly and has participated in educational conferences on the topics neuroendocrine tumors and acromegaly sponsored by Novartis and Ipsen. Dr. Hehmke declares no conflict of interest. Prof. Krabbe declares no direct conflict with this article. He has served on the Advisory Board of Lilly and as speaker for Berlin-Chemie, Amgen, and MSD Sharp & Dohme \/ Merck & Co. Inc.Figure and Table legends are provided within the respective text sections.Reference [] and parts of the table from it are available as open access article and for reproduction use as long as the source is acknowledged \/ cited which is the case here.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}